|本期目录/Table of Contents|

生物材料补片在贲门癌根治术中的临床疗效

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R]

期数:
2019年20期
页码:
3657-3659
栏目:
论着(消化·泌尿系肿瘤)
出版日期:
2019-09-08

文章信息/Info

Title:
The clinical use of biomaterial patch in cardiac cancer surgery
作者:
洪 流1;?韩 宇2;?周 威1;?杨万里1;?石高凯1
1.空军军医大学西京医院消化病医院,陕西 西安 710032;2.空军军医大学西京医院耳鼻咽喉头颈外科,陕西 西安 710032
Author(s):
Hong Liu1;?Han Yu2;?Zhou Wei1;?Yang Wanli1;?Shi Gaokai1
1.Xijing Hospital of Digestive Diseases,Air Force Military Medical University,Shaanxi Xi'an 710032,China;2.Department of ENT,Xijing Hospital,Air Force Military Medical University,Shaanxi Xi'an 710032,China.
关键词:
贲门癌;?生物材料补片;?外科手术
Keywords:
cardiac cancer;?biomaterial patch;?surgery
分类号:
R735.2
DOI:
10.3969/j.issn.1672-4992.2019.20.024
文献标识码:
A
qq自动领红包软件:
目的:探讨生物材料补片在贲门癌根治术中的临床疗效。方法:回顾性对比分析64例经膈肌裂孔行贲门癌根治术的患者的临床资料,患者随机分为实验组(n=30)和对照组(n=34)。实验组用生物材料补片进行食管空肠吻合口加固和悬吊,对照组不使用生物材料补片进行加固和悬吊。结果:两组患者的临床资料具有可比性。实验组的患者肺部感染发生率明显降低(P<0.05),但两组的吻合口瘘和吻合口狭窄发生率无明显差异。两组在手术时间、术中出血量、首次排气时间、住院时间等方面无统计学差异。结论:生物材料补片在贲门癌手术中具有良好的生物相容性和安全性,可能通过修补膈肌裂孔降低了肺部感染的发生率。
Abstract:
Objective:To evaluate the clinical value of of biomaterial patch in cardiac cancer surgery.Methods:Totally 64 consecutive cardiac cancer patients receiving radical operations through diaphragmatic hiatus were involved in this retrospective study.The patients were randomly divided into the experimental group (n=30),which used biomaterial patch,and the control group(n=34) without using biomaterial patch.Results:The clinical information of two groups was comparable.The incidence of pulmonary infection in the experimental group was significantly less than that in the control group (P<0.05).There was no statistical difference between two groups in the incidence of anastomotic leakage and anastomotic stenosis,operative time,blood loss during operation,first flatus time and hospitalization time.Conclusion:The biomaterial patch was biocompatible and safe in cardiac cancer surgery,and it might be helpful to reduce the incidence of pulmonary infection by repairing diaphragmatic hiatus.

参考文献/References

[1]Jang Y,Kim J,Shim JW,et al.Primary cardiac angiosarcoma:A prolonged response to surgical resection followed by concurrent chemoradiotherapy with docetaxel [J].Springerplus,2016(5):648.
[2]Gramaticu IM,Croitoru AE.Current management of gastric cancer in Europe [J].Chirurgia (Bucur),2018,113(6):758-764.
[3]Huang J,Zhou Y,Wang C,et al.Logistic regression analysis of the risk factors of anastomotic fistula after radical resection of esophageal-cardiac cancer [J].Thorac Cancer,2017,8(6):666-671.
[4]Qiu B,Feng F,Gao S.Partial esophagogastrostomy with esophagogastric anastomosis below the aortic arch in cardiac carcinoma:Characteristics and treatment of postoperative anastomotic leakage[J].J Thorac Dis,2015,7(11):1994-2002.
[5]Ostdiek AM,Ivey JR,Grant DA,et al.An in vivo study of a gold nanocomposite biomaterial for vascular repair[J].Biomaterials,2015(65):175-183.
[6]SHAO Zhongfu,ZHANG Jinye,CHEN Yongdong,et al.Application of biomaterial patch in esophageal cancer surgery [J].Modern Oncology,2013,21(06):1225-1227.[邵中夫,张金野,陈永东,等.生物修补膜在食管癌手术中的应用研究[J].现代肿瘤医学,2013,21(06):1225-1227.]
[7]Park CH,Park JC,Chung H,et al.A specific role of endoscopic ultrasonography for therapeutic decision-making in patients with gastric cardia cancer [J].Surg Endosc,2016,30(10):4193-4199.
[8]Kanaji S,Suzuki S,Matsuda Y,et al.Recent updates in perioperative chemotherapy and recurrence pattern of gastric cancer [J].Ann Gastroenterol Surg,2018,2(6):400-405.
[9]Park R,Williamson S,Kasi A,et al.Immune therapeutics in the treatment of advanced gastric and esophageal Cancer [J].Anticancer Res,2018,38(10):5569-5580.
[10]Gramaticu IM,Croitoru AE.Current management of gastric cancer in Europe [J].Chirurgia (Bucur),2018,113(6):758-764.
[11]MA Yubo,HONG Liu.The outcomes of patients receiving different thoracoabdominal cardia cancer radical operations [J].Modern Oncology,2016,24(04):588-590.[马玉帛,洪流.改良式胸腹联合贲门癌根治术的临床疗效[J].现代肿瘤医学,2016,24(04):588-590.]
[12]Rawicz-Pruszyński K,van Sandick JW,Mielko J,et al.Current challenges in gastric cancer surgery:European perspective [J].Surg Oncol,2018,27(4):650-656.
[13]Mehta R,Shah A,Almhanna K.Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer:an evidence-based review of place in therapy [J].Onco Targets Ther,2018(11):6525-6537.
[14]Fukuchi M,Mochiki E,Ishiguro T,et al.Prognostic significance of conversion surgery following first- or second-line chemotherapy for unresectable gastric cancer [J].Anticancer Res,2018,38(11):6473-6478.
[15]Kajitani M,Wadia Y,Hinds MT,et al.Successful repair of esophageal injury using an elastin based biomaterial patch [J].ASAIO J,2001,47(4):342-345.
[16]Chantawong P,Tanaka T,Uemura A,et al.Silk fibroin-Pellethane cardiovascular patches:Effect of silk fibroin concentration on vascular remodeling in rat model [J].J Mater Sci Mater Med,2017,28(12):191.

备注/Memo

备注/Memo:
National Natural Science Foundation of China(No.81870719);国家自然科学基金项目(编号:81870719)
更新日期/Last Update: 1900-01-01